Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
2.520
+0.030 (1.20%)
At close: Apr 17, 2026, 4:00 PM EDT
2.530
+0.010 (0.40%)
After-hours: Apr 17, 2026, 7:34 PM EDT

Kiora Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
--2.455.967.85
Short-Term Investments
8.3923---
Cash & Short-Term Investments
8.39232.455.967.85
Cash Growth
-63.51%836.98%-58.85%-24.06%562.46%
Accounts Receivable
1.520.6---
Other Receivables
1.790.272.051.370.53
Total Trade Receivables
3.320.872.051.370.53
Other Current Assets
0.2-0.230.340.61
Total Current Assets
11.9123.874.747.688.99
Net Property, Plant & Equipment
0.380.060.110.170.28
Other Intangible Assets
2.066.698.8110.7410.77
Other Long-Term Assets
0.060.030.050.080.09
Total Assets
24.2536.4813.7118.6820.13
Accounts Payable
--0.211.010.16
Accrued Expenses
--1.381.841.33
Current Portion of Leases
0.160.020.050.110.12
Other Current Liabilities
-0.98-0.32-
Total Current Liabilities
0.1611.633.271.61
Long-Term Leases
0.20.030.06-0.09
Other Long-Term Liabilities
4.294.685.9143.85
Total Long-Term Liabilities
4.54.725.9743.94
Total Liabilities
8.1310.727.67.275.55
Preferred Stock
00---
Common Stock
0.280.270.080.020
Additional Paid-in Capital
170.32169.16153.19146.04135.54
Accumulated Other Comprehensive Income
-0.25-0.28-0.18-0.18-0.09
Retained Earnings
-154.22-143.38-146.98-134.46-120.88
Shareholders' Equity
16.1325.766.1111.4114.58
Total Liabilities & Equity
24.2536.4813.7118.6820.13
Total Debt
0.370.060.110.110.21
Net Cash (Debt)
8.0222.942.355.867.65
Net Cash Growth
-65.03%877.20%-59.93%-23.37%1150.70%
Net Cash Per Share
1.965.564.3672.00285.39
Book Value
16.1325.766.1111.4114.58
Book Value Per Share
3.936.2411.36140.20544.22
Tangible Book Value
14.0619.07-2.70.663.81
Tangible Book Value Per Share
3.434.62-5.038.17142.26
Updated Mar 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q